Status:
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lead Sponsor:
Hoffmann-La Roche
Collaborating Sponsors:
Chugai Pharmaceutical
Conditions:
Non-Small Cell Lung Cancer
KRAS G12C Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
October 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2030
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06793215
Start Date
October 24 2025
End Date
October 31 2030
Last Update
March 12 2026
Active Locations (195)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Oncology and Hematology
Anchorage, Alaska, United States, 99508
2
Marin Cancer Care Inc
Greenbrae, California, United States, 94904
3
Hoag Memorial Hospital
Newport Beach, California, United States, 92658
4
BioResearch Partner
Hialeah, Florida, United States, 33013